Core Insights - Absci has appointed Mary Szela, a veteran biopharmaceutical executive, to its Board of Directors, bringing over three decades of commercial and clinical leadership experience [1][2] - Szela's expertise includes the global launch and expansion of Humira, a highly successful therapy, and she has held significant roles in various biopharmaceutical companies [2][3] - Absci is focused on accelerating the development of its AI-designed therapeutics, including ABS-101 for inflammatory bowel disease and ABS-201 for androgenetic alopecia [3][4] Company Overview - Absci is a clinical-stage biopharmaceutical company utilizing generative AI to create innovative biologics, aiming to enhance drug discovery and development processes [4] - The company's Integrated Drug Creation™ platform combines advanced AI models with synthetic biology, facilitating rapid design and validation of therapeutics [4] - Absci's pipeline includes ABS-101, an anti-TL1A antibody for inflammatory bowel disease, and ABS-201, an anti-prolactin receptor antibody for androgenetic alopecia, with clinical developments expected in the near future [3][4]

Core Insights - Artiva Biotherapeutics has appointed Dr. Subhashis Banerjee as Chief Medical Officer, enhancing its development team focused on autoimmune diseases and cell therapy [1][2] - Dr. Banerjee has over 20 years of clinical development experience, previously holding significant roles at Bristol Myers Squibb and VYNE Therapeutics [1][2] - The company aims to advance its AlloNK® program for treating B-cell driven autoimmune diseases, leveraging Dr. Banerjee's expertise in regulatory approval of major therapies [2][5] Company Overview - Artiva Biotherapeutics is a clinical-stage biotechnology company dedicated to developing safe and effective cell therapies for autoimmune diseases and cancers [5][6] - The lead program, AlloNK®, is a non-genetically modified NK cell therapy designed to enhance the efficacy of monoclonal antibodies for B-cell depletion [5] - Artiva was founded in 2019 as a spin-out from GC Cell, holding exclusive rights to NK cell manufacturing technology outside of Asia, Australia, and New Zealand [5] Recent Appointments - Dr. David Moriarty has been appointed as SVP of Clinical Operations, bringing nearly 25 years of experience in clinical research related to cell therapy and autoimmune diseases [3][4] - Benjamin Dewees has joined as SVP of Regulatory Affairs, with over 25 years of experience in regulatory affairs across various therapeutic areas [9] - Feng Xu has been appointed as SVP of Biometrics, contributing over 20 years of clinical development experience, including successful global regulatory filings [9]